Clinical Trial

Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly

Study acronym: ROPE
Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this non interventional study is to evaluate symptom burden in adult patients with PV without symptomatic splenomegaly during treatment with ropeginterferon alfa-2b in a real-world setting. Further patient-relevant endpoints include effectiveness including complete hematologic response (CHR), event-free survival (EFS), safety and tolerability, treatment reality including dosing details as well as factors affecting treatment decision making.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-12-16; most recent amendment 2026-01-08.
Trial Details
NCT Number NCT06743035
Lead Sponsor iOMEDICO AG
Collaborators: AOP Orphan Pharmaceuticals Germany GmbH
Conditions Polycythemia Vera
Enrollment 200 participants
Start Date 2024-12-03
Primary Completion 2029-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-09